Showing results (241-250 of 305) with videos related to
Sort By:
Pageof 31
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.Annals of Hematology|October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.American Journal of Hematology|October 10, 2012
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profilesLaura Mosca, Pellegrino Musto, Katia Todoerti, et al.Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.Blood|July 22, 2004
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialAntonio Palumbo, Sara Bringhen, Maria Teresa Petrucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2013
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemiaMarta Lionetti, Pellegrino Musto, Maria Teresa Di Martino, et al.Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.Pageof 31